AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.680
-0.020 (-0.74%)
Dec 20, 2024, 4:00 PM EST - Market closed
AC Immune Employees
As of December 31, 2023, AC Immune had 161 total employees, including 133 full-time and 28 part-time employees. The number of employees increased by 5 or 3.21% compared to the previous year.
Employees
161
Change (1Y)
5
Growth (1Y)
3.21%
Revenue / Employee
$301,276
Profits / Employee
-$293,114
Market Cap
265.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Accolade | 2,400 |
| Zynex | 1,100 |
| COMPASS Pathways | 186 |
| iTeos Therapeutics | 157 |
| ProQR Therapeutics | 157 |
| 4D Molecular Therapeutics | 147 |
| Senseonics Holdings | 132 |
| Atea Pharmaceuticals | 75 |
ACIU News
- 5 weeks ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 5 months ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 5 months ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha
- 5 months ago - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease - GlobeNewsWire
- 7 months ago - AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 - GlobeNewsWire
- 7 months ago - Alzheimer's vaccine licensing deal boosts AC Immune - Market Watch
- 7 months ago - AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 months ago - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease - Business Wire